Tech Company Financing Transactions

Excision BioTherapeutics Funding Round

Excision BioTherapeutics, based in San Francisco, scored $60 million from Greatpoint Ventures Innovation Fund, Adjuvant Capital and Anzu Partners.

Transaction Overview

Company Name
Excision BioTherapeutics
Announced On
2/18/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Undisclosed
Investors

Greatpoint Ventures Innovation Fund (Lead Investor) (Ashok Krishnamurthi)

Adjuvant Capital

Anzu Partners

ARTIS Ventures (Stuart Peterson)

Cota Capital

IndusAge Partners

Loreda Holding

Norwest Venture Partners

Olive Tree Capital

WRVI Capital

Proceeds Purpose
The proceeds will be used to advance Excision's lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
988 Market St.
San Francisco, CA 94102
USA
Phone
Undisclosed
Website
www.excisionbio.com
Email Address
[email protected]
Overview
Excision BioTherapeutics Inc. is a life science company focused on the development and commercialization of advanced gene editing therapeutics for the treatment and eradication of life-threatening disease caused by neurotropic viruses (viral infections).
Profile
Excision BioTherapeutics LinkedIn Company Profile
Social Media
Excision BioTherapeutics Company Twitter Account
Company News
Excision BioTherapeutics News
Facebook
Excision BioTherapeutics on Facebook
YouTube
Excision BioTherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Daniel Dornbusch
  Daniel Dornbusch LinkedIn Profile  Daniel Dornbusch Twitter Account  Daniel Dornbusch News  Daniel Dornbusch on Facebook
Chief Medical Officer
Revati Shreeniwas
  Revati Shreeniwas LinkedIn Profile  Revati Shreeniwas Twitter Account  Revati Shreeniwas News  Revati Shreeniwas on Facebook
Chief Scientific Officer
TJ Cradick
  TJ Cradick LinkedIn Profile  TJ Cradick Twitter Account  TJ Cradick News  TJ Cradick on Facebook
Chief Scientific Officer
Kamel Khalili
  Kamel Khalili LinkedIn Profile  Kamel Khalili Twitter Account  Kamel Khalili News  Kamel Khalili on Facebook
VP - Bus. Development
Michael Aberman
  Michael Aberman LinkedIn Profile  Michael Aberman Twitter Account  Michael Aberman News  Michael Aberman on Facebook
VP - R & D
Jenn Gordon
  Jenn Gordon LinkedIn Profile  Jenn Gordon Twitter Account  Jenn Gordon News  Jenn Gordon on Facebook
VP - Regulatory Affairs
Patricia Williams
  Patricia Williams LinkedIn Profile  Patricia Williams Twitter Account  Patricia Williams News  Patricia Williams on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/18/2021: Mundi venture capital transaction
Next: 2/18/2021: Elicio Therapeutics venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We record all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.